Compare VENUS REMEDIES with WYETH LTD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs WYETH LTD - Comparison Results

WYETH LTD 
   Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES WYETH LTD VENUS REMEDIES/
WYETH LTD
 
P/E (TTM) x -1.1 27.7 - View Chart
P/BV x 0.1 5.3 1.4% View Chart
Dividend Yield % 0.0 1.3 -  

Financials

 VENUS REMEDIES   WYETH LTD
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
WYETH LTD
Mar-13
VENUS REMEDIES/
WYETH LTD
5-Yr Chart
Click to enlarge
High Rs1261,044 12.1%   
Low Rs61818 7.5%   
Sales per share (Unadj.) Rs301.8298.6 101.1%  
Earnings per share (Unadj.) Rs-24.957.2 -43.4%  
Cash flow per share (Unadj.) Rs2.558.4 4.4%  
Dividends per share (Unadj.) Rs017.00 0.0%  
Dividend yield (eoy) %01.8 0.0%  
Book value per share (Unadj.) Rs293.3249.5 117.6%  
Shares outstanding (eoy) m12.3422.72 54.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.33.1 9.9%   
Avg P/E ratio x-3.816.3 -23.1%  
P/CF ratio (eoy) x36.715.9 230.5%  
Price / Book Value ratio x0.33.7 8.5%  
Dividend payout %029.7 0.0%   
Avg Mkt Cap Rs m1,15421,157 5.5%   
No. of employees `0000.90.5 188.0%   
Total wages/salary Rs m393400 98.3%   
Avg. sales/employee Rs Th4,026.113,787.4 29.2%   
Avg. wages/employee Rs Th425.0813.0 52.3%   
Avg. net profit/employee Rs Th-331.82,643.3 -12.6%   
INCOME DATA
Net Sales Rs m3,7246,783 54.9%  
Other income Rs m23353 6.4%   
Total revenues Rs m3,7477,136 52.5%   
Gross profit Rs m3951,617 24.4%  
Depreciation Rs m33827 1,271.8%   
Interest Rs m3546 6,441.8%   
Profit before tax Rs m-2751,938 -14.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-5 0.0%   
Tax Rs m32632 5.0%   
Profit after tax Rs m-3071,301 -23.6%  
Gross profit margin %10.623.8 44.5%  
Effective tax rate %-11.532.6 -35.2%   
Net profit margin %-8.219.2 -43.0%  
BALANCE SHEET DATA
Current assets Rs m2,6386,984 37.8%   
Current liabilities Rs m2,3052,056 112.1%   
Net working cap to sales %8.972.6 12.3%  
Current ratio x1.13.4 33.7%  
Inventory Days Days13599 136.4%  
Debtors Days Days4624 193.5%  
Net fixed assets Rs m4,871244 1,993.8%   
Share capital Rs m123227 54.3%   
"Free" reserves Rs m3,4965,441 64.2%   
Net worth Rs m3,6195,668 63.9%   
Long term debt Rs m1,37425 5,497.6%   
Total assets Rs m7,5097,901 95.0%  
Interest coverage x0.2353.3 0.1%   
Debt to equity ratio x0.40 8,610.0%  
Sales to assets ratio x0.50.9 57.8%   
Return on assets %0.616.5 3.8%  
Return on equity %-8.522.9 -37.0%  
Return on capital %1.634.0 4.6%  
Exports to sales %00.2 0.0%   
Imports to sales %13.936.3 38.2%   
Exports (fob) Rs mNA15 0.0%   
Imports (cif) Rs m5172,465 21.0%   
Fx inflow Rs m015 0.0%   
Fx outflow Rs m5172,677 19.3%   
Net fx Rs m-517-2,662 19.4%   
CASH FLOW
From Operations Rs m514923 55.7%  
From Investments Rs m-123317 -38.8%  
From Financial Activity Rs m-387-481 80.5%  
Net Cashflow Rs m4759 0.6%  

Share Holding

Indian Promoters % 32.9 0.0 -  
Foreign collaborators % 0.0 51.1 -  
Indian inst/Mut Fund % 0.2 11.3 1.6%  
FIIs % 0.6 7.2 8.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 30.4 218.4%  
Shareholders   20,121 21,978 91.6%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   JUBILANT LIFE SCIENCES  PANACEA BIOTECH  CADILA HEALTHCARE  ABBOTT INDIA  PLETHICO PHARMA  

Compare VENUS REMEDIES With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 21 Points Higher; Banking and Oil & Gas Stocks Witness Buying(Closing)

Indian share markets witnessed buying interest during closing hours today and ended their day marginally higher.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of VENUS REMEDIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of VENUS REMEDIES. Also includes updates on the valuation of VENUS REMEDIES.

VENUS REMEDIES Announces Quarterly Results (2QFY19); Net Profit Down 16.3% (Quarterly Result Update)

Nov 23, 2018 | Updated on Nov 23, 2018

For the quarter ended September 2018, VENUS REMEDIES has posted a net profit of Rs 8 m (down 16.3% YoY). Sales on the other hand came in at Rs 809 m (down 10.6% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (1QFY19); Net Profit Down 756.1% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, VENUS REMEDIES has posted a net profit of Rs 56 m (down 756.1% YoY). Sales on the other hand came in at Rs 655 m (down 16.2% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

More Views on News

Most Popular

Is Hawkins Set to Become Our Next Superhero Stock?(The 5 Minute Wrapup)

Nov 1, 2019

After PI Industries, Hawkins has put up a stellar show so far.

Ditch the Risky Fixed Deposits for Safer 'Bluechip Deposits'(Profit Hunter)

Oct 30, 2019

Most people think stocks are riskier than fixed deposits and bonds. The last quarter century proves otherwise.

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Nov 11, 2019 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 8-QTR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS